Q-omics provides the consensus-scored CCDC185 profile across patient tissues and cancer cell-line models. CCDC185 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CCDC185 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, CCDC185 RNA expression shows 11,895 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, THCA, and KIRP as cancer lineages where CCDC185 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC185 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC185 survival associations across molecular data types. CCDC185 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC185 RNA expression–survival associations across cancer types. High CCDC185 expression shows unfavorable associations in UVM, STAD, KIRC, COAD, LIHC and KICH. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CCDC185 RNA expression.
This table summarizes CCDC185 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC185. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC185 shows lower tumor expression in KICH and KIRC and higher tumor expression in THCA, LUAD, LUSC and BRCA. The THCA box plot shows higher CCDC185 RNA expression in tumor versus normal tissue (log2 FC = +0.103, t-test p < 0.001).
This table shows molecular features associated with CCDC185 in patient tissues and cancer cell lines. In patient samples, CCDC185 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC185 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and OVARY.
